N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells.

@article{Simeone2005N4HydroxyphenylretinamideIM,
  title={N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells.},
  author={A Simeone and Chu-xia Deng and Gary j. Kelloff and Vernon E. Steele and Marcella M. Johnson and Ana Maria Tari},
  journal={Carcinogenesis},
  year={2005},
  volume={26 5},
  pages={1000-7}
}
Women with germline mutations in the breast cancer susceptibility gene BRCA1 are at an increased risk of developing breast cancer. The synthetic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) has been shown to have a clinical chemopreventive activity in patients with premenopausal breast cancer. Since BRCA1 mutations are associated with an early-onset… CONTINUE READING